Differential diagnosis between functional and organic intestinal disorders: Is there a role for non-invasive tests?

World Journal of Gastroenterology

Volumn 13, Issue 2, 2007, Pages 219-223

  Costa, Francesco ^a   Mumolo, Maria Gloria ^a   Marchi, Santino ^a   Bellina, Massimo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Faecal markers; Functional bowel disorders; Intestinal diseases; Intestinal inflammation

Indexed keywords

CALPROTECTIN; DNA; LACTOFERRIN; PANCREATIC ELASTASE; SORBITOL;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; BREATH ANALYSIS; CHRONIC PANCREATITIS; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DEFECATION HABIT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENDOSCOPY; ENTERITIS; ENTEROPATHY; FECES ANALYSIS; GASTROINTESTINAL MOTILITY; HUMAN; IRRITABLE COLON; MALABSORPTION; PATIENT COMPLIANCE; PATIENT SELECTION; PUBLIC HEALTH; REVIEW; ULCERATIVE COLITIS;

EID: 33846931875     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i2.219     Document Type: Review

References (60)

1. Drossman DA. Functional GI disorders: what's in a name? Gastroenterology 2005; 128: 1771-1772
2. Christensen J. Heraclides or the physician. Gastroenterol Int 1990; 3: 45-48
3. Gershon MD. Review article: roles played by 5-hydroxy-tryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 Suppl 2: 15-30
4. Camilleri M. Pharmacogenomics and functional gastrointestinal disorders. Pharmacogenomics 2005; 6: 491-501
5. Bellini M, Rappelli L, Blandizzi C, Costa F, Stasi C, Colucci R, Giannaccini G, Marazziti D, Betti L, Baroni S, Mumolo MG, Marchi S, Del Tacca M. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol 2003; 98: 2705-2711
6. Drossman DA. Mind over matter in the postinfective irritable bowel. Gut 1999; 44: 306-307
7. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311
8. Drossman DA. The functional gastrointestinal disorders and the Rome H process. Gut 1999; 45 Suppl 2: II1-II5
9. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304: 87-90
10. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 78-82
11. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131
12. Gladman LM, Gorard DA. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. Aliment Pharmacol Ther 2003; 17: 651-654
13. Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992; 102: 1962-1967
14. Bellini M, Tosetti C, Costa F, Biagi S, Stasi C, Del Punta A, Monicelli P, Mumolo MG, Ricchiuti A, Bruzzi P, Marchi S. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Dig Liver Dis 2005; 37: 934-939
15. Vandvik PO, Aabakken L, Farup PG. Diagnosing irritable bowel syndrome: poor agreement between general practitioners and the Rome II criteria. Scand J Gastroenterol 2004; 39: 448-453
16. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
17. Cronin CC, Shanahan F. Immunological tests to monitor inflammatory bowel disease-have they delivered yet? Am J Gastroenterol 1998; 93: 295-297
18. Gabay C, Kushner I. Acute-phase proteins and other systemic responses-to inflammation. N Engl J Med 1999; 340: 448-454
19. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New insights into the biology of the acute phase response. J Clin Immunol 1999; 19: 203-214
20. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402-408
21. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-2714
22. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NK Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702
23. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-93
24. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459-1464
25. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309-1314
26. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 2831-2837
27. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-513
28. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem 1983; 134: 1-6
29. Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the LI leukocyte protein). In: Smith V, Dedman JR. Stimulus Response Coupling: the role of intracellular calcium-binding proteins. Boca Raton FL: CRC Press Inc 1990: 187-210
30. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protem. Digestion 1997; 58: 176-180
31. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-647
32. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott Y, Moshakis V, Reynolds JR. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46: 795-800
33. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362-366
34. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004; 20: 615-621
35. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-54
36. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22
37. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368
38. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-460
39. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927-934
40. Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, Lin D, Connor JT, Fazio VW, Lashner BA. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126: 1280-1286
41. Sidransky D, Tokinc, T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105
42. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test Gut 1996; 39: 580-586
43. Glasbrenner B, Schon A, Klatt S, Beckh Y, Adler G. Clinical evaluation of the faecal elastase test in the diagnosis and staging of chronic pancreatitis. Eur J Gastroenterol Hepatol 1996; 8: 1117-1120
44. Thomas PD, Forbes A, Green J, Howdle P, Long R, Playford R, Sheridan M, Stevens R, Valori R, Walters J, Addison GM, Hill P, Brydon G. Guidelines for the investigation of chronic diarrhoea, 2nd ed. Gut 2003; 52 Suppl 5: v1-v15
45. Levitt MD. Production and excretion of hydrogen gas in man. N Engl J Med 1969; 281: 122-127
46. Bohmer CJ, Tuynman HA. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. Eur J Gastroenterol Hepatol 2001; 13: 941-944
47. Farup PG, Monsbakken KW, Vandvik PO. Lactose malabsorption in a population with irritable bowel syndrome: prevalence and symptoms. A case-control study. Scand J Gastruenterol 2004; 39: 645-649
48. Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 1990; 99: 1016-1020
49. Teo M, Chung S, Chitti L, Tran C, Kritas S, Butler R, Cummins A. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastroenterol Hepatol 2004, 19: 904-909
50. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Deviere J, Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53: 987-992
51. Quigley EM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005; 6: 122-132
52. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506
53. Vantrappen GR, Rutgeerts; PJ, Ghoos YF, Hiele MI. Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. Gastroenterology 1989; 96: 1126-1134
54. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104: 1640-1647
55. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275: 622-629
56. Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-303
57. Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126: 1721-1732
58. Monsbakken KW, Vandvik PO, Farup PG.Perceived food intolerance in subjects with irritable bowel syndrome - etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667-672
59. Sampson HA, Sicherer SH, Birnbaum AH. AGA technical review on the evaluation of food allergy in gastrointestinal disorders. American Gastroenterological Association. Gastroenterology 2001; 120: 1026-1040
60. Zar S, Benson MJ, Kumar D. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 1550-1557